More stories

  • in

    Prasugrel Outshines Rival Drugs After Invasive Coronary Care

    Source link : https://newshealth.biz/health-news/prasugrel-outshines-rival-drugs-after-invasive-coronary-care/ Among commonly used antiplatelet agents, prasugrel offers the most optimal balance between efficacy and safety after invasive management of patients with coronary syndrome, a meta-analysis finds. Medscape Medical News Source link : https://www.medscape.com/viewarticle/prasugrel-outshines-rival-drugs-after-invasive-coronary-care-2026a1000i8y?src=rss Author : Publish date : 2026-06-02 05:30:00 Copyright for syndicated content belongs to the linked Source. The post Prasugrel Outshines Rival Drugs After […] More

  • in

    Psychotropics Linked to Increased BMI, CVD Risk

    Source link : https://newshealth.biz/health-news/psychotropics-linked-to-increased-bmi-cvd-risk/ Psychotropics are associated with increased BMI, and users with a high BMI genetic risk score and an unhealthy lifestyle have triple the risk for CVD, new research shows. Medscape Medical News Source link : https://www.medscape.com/viewarticle/psychotropics-linked-increased-bmi-cvd-risk-2026a1000i8n?src=rss Author : Publish date : 2026-06-02 03:35:00 Copyright for syndicated content belongs to the linked Source. The post Psychotropics Linked to […] More

  • in

    ‘Transformative’ pancreatic cancer drug doubles survival time

    Source link : https://newshealth.biz/health-news/transformative-pancreatic-cancer-drug-doubles-survival-time/ The drug daraxonrasib is being put forward to treat people with advanced pancreatic cancer in clinics REUTERS/Danielle Villasana A daily pill doubles the survival time of people with pancreatic cancer, one of the most aggressive and difficult-to-treat forms of the condition, even after they have stopped responding to chemotherapy. What’s more, the convenient pill has […] […] More

  • in

    CELMoD Drug Cuts Risk of Myeloma Progression, Death by 52% in Trial

    Source link : https://newshealth.biz/health-news/celmod-drug-cuts-risk-of-myeloma-progression-death-by-52-in-trial/ CHICAGO — Adding a novel cereblon E3 ligase modulation (CELMoD) drug to a standard multiple myeloma regimen significantly improved progression-free survival (PFS) in a vulnerable population of patients with relapsed or refractory disease, a phase III trial showed. In participants largely refractory to lenalidomide (Revlimid) and an anti-CD38 antibody, median PFS reached 18 months with […] […] More

  • in

    AI Spots Undertreated Heart Failure Risk Early

    Source link : https://newshealth.biz/health-news/ai-spots-undertreated-heart-failure-risk-early/ An AI tool applied to NHS health records identified stable-appearing heart failure patients who were undertreated and at high risk before hospital admission. Medscape News UK Source link : https://www.medscape.com/viewarticle/ai-spots-undertreated-heart-failure-risk-early-2026a1000i88?src=rss Author : Publish date : 2026-06-01 19:45:00 Copyright for syndicated content belongs to the linked Source. The post AI Spots Undertreated Heart Failure Risk Early first […] More

  • in

    Tenecteplase Unseats Low-Dose Alteplase Favored for Asian Patients

    Source link : https://newshealth.biz/health-news/tenecteplase-unseats-low-dose-alteplase-favored-for-asian-patients/ T-FLAVOR investigators compared tenecteplase with low-dose alteplase in stroke patients scheduled for endovascular therapy (EVT). The trial notably took place in Japanese patients, believed to be more susceptible to bleeding, for whom low-dose alteplase is still standard of care. More work is needed given concerns that tenecteplase may affect clot migration and distal embolization in […] […] More

  • in

    Non-Operative Treatment for CRC May Include Observation After Complete Response

    Source link : https://newshealth.biz/health-news/non-operative-treatment-for-crc-may-include-observation-after-complete-response/ CHICAGO — Patients who skipped maintenance therapy after a complete response to upfront treatment with a PD-1 inhibitor lived just as long as those who had 3 years of maintenance, data from a cohort study that compared nonsurgical colorectal cancer (CRC) options showed. After more than 3 years of follow-up, patients who entered surveillance had […] […] More

  • in

    Patients With Tardive Dyskinesia Symptoms May Go Undiagnosed

    Source link : https://newshealth.biz/health-news/patients-with-tardive-dyskinesia-symptoms-may-go-undiagnosed/ Tardive dyskinesia (TD), a movement disorder that causes involuntary movements often triggered by antipsychotic exposure, has appeared in the DSM for decades. Despite advancements in diagnostic tools and treatments, TD still goes unrecognized in many cases. “Tardive dyskinesia continues to be a prevalent and clinically significant condition, particularly among older adults, women, and long-term antipsychotic […] […] More

  • in

    Obesity With a Normal BMI? Study Suggests It’s Common

    Source link : https://newshealth.biz/health-news/obesity-with-a-normal-bmi-study-suggests-its-common/ Over 26% of U.S. adults with a normal BMI met new criteria for clinical obesity proposed by the Lancet commission. About 78% of adults had excess adiposity if defined by using two or three abnormal body measurements. Researchers called for studies to determine whether screening with the new obesity framework actually improves downstream health outcomes. […] […] More

  • in

    Targeted Combo Boosts PFS in BRAF-Mutant Metastatic Colorectal Cancer

    Source link : https://newshealth.biz/health-news/targeted-combo-boosts-pfs-in-braf-mutant-metastatic-colorectal-cancer/ CHICAGO — Adding encorafenib (Braftovi) and cetuximab (Erbitux) to FOLFIRI chemotherapy significantly improved progression-free survival (PFS) as first-line treatment of BRAF V600E-mutated metastatic colorectal cancer, according to secondary analysis of a randomized trial. Results from cohort 3 of the BREAKWATER trial showed that adding the two targeted therapies to FOLFIRI (leucovorin, fluorouracil, and irinotecan) chemotherapy […] […] More

  • in

    FDA Approves Cefepime-Zidebactam for Complicated UTIs

    Source link : https://newshealth.biz/health-news/fda-approves-cefepime-zidebactam-for-complicated-utis/ The novel IV antibiotic combination works ‘synergistically’ to combat gram-negative pathogens in complicated UTIs and pyelonephritis. Medscape Medical News Source link : https://www.medscape.com/viewarticle/fda-approves-cefepime-zidebactam-complicated-utis-2026a1000i8a?src=rss Author : Publish date : 2026-06-01 19:55:00 Copyright for syndicated content belongs to the linked Source. The post FDA Approves Cefepime-Zidebactam for Complicated UTIs first appeared on News Health. —- Author : News […] More

  • in

    The Pro-Life Movement’s Cruelty Problem

    Source link : https://newshealth.biz/health-news/the-pro-life-movements-cruelty-problem/ She stays quiet because of her child, my patient tells me. But despite her passivity, her husband always manages to find something wrong with her. He shouts at ungodly volumes, threatening, “Don’t make me do something to you that I’ll regret!” Another time, “You’re making me angry enough to hit you!” She invariably cowers in […] […] More

Load More
Congratulations. You've reached the end of the internet.